Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis

摘要: Background: Expression of estrogen receptor beta (ERβ) is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although the expression ERβ has been reported to correlate with better prognosis NSCLC most literatures, some controversies still exist. Since limited patient numbers within independent studies, here we performed meta-analysis clarify correlations between NSCLC. Materials methods: We final analysis 2279 patients from 14 evaluable studies for Prognostic Value overexpression (up October 2014). Data eligible were extracted included into using random effects model. Studies pooled. Summary hazard ratios (HR) calculated. Results: Our study shows that pooled ratio overall survival was 0.78 [95% confidence interval (CI): 0.62-0.98] by univariate 1.06 (95% CI: 0.70-1.61) multivariate analysis. Pooled HR American Japan 1.09 0.95-1.25, P=0.239) 6 reported, however, 0.57 0.46-0.70) outside 8 reported. 0.75 0.60-0.94) N-ERβ 0.76 0.51-1.12) C-ERβ. Conclusion: results suggested significant associated good on but not outcome Japan. Overexpression had survival. Large prospective are now needed confirm clinical utility as an marker.